ARHGAP17 Inhibits Hepatocellular Carcinoma Progression by Inactivation of Wnt/β-Catenin Signaling Pathway
Biochemical Genetics · 2025
DOI: 10.1007/s10528-024-10822-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Genetics, 2025. Verfasst von Sirui Fan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Training Base, General Hospital of Northern Theater Command of Jinzhou Medical University, Shenyang, 110016, Liaoning, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Wnt Signaling Pathway, GTPase-Activating Proteins. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, the Joint Program of Key R&D Programs of Liaoning Province, the R&D PROGRAMME FOR MAJOR technological innovations of Shenyang City.
Abstract (Originalsprache)
As a member of Rho GAPs family, Rho GTPase-Activating Protein 17 (ARHGAP17) regulates cytoskeletal recombination, cell polarity, cell proliferation and cell migration. ARHGAP17 is identified as a tumor suppressor in numerous cancer types. Current study intends to examine ARHGAP17 expression and its possible influence on the progression of hepatocellular carcinoma (HCC). ARHGAP17 expression in HCC cells was verified by RT-PCR and western blot. The proliferation and invasion of HCC cells were evaluated by CCK8 assay and transwell assay, respectively. The mRNA expression of ARHGAP17, PCNA, E-cadherin, N-cadherin, β-catenin, GSK-3β, Axin1, and APC were detected by RT-PCR. The protein expression of ARHGAP17, PCNA, E-cadherin, N-cadherin, β-catenin, p-β-catenin, GSK-3β, p-GSK-3β, Axin1, and APC were detected by western blot. ARHGAP17 staining was evaluated by immunohistochemistry and immunofluorescence. ARHGAP17 expression decreased significantly in HCC tumors and HCC cells after EMT. In response to overexpression of ARHGAP17, the capacities of HCC cell proliferation and invasion were reduced significantly, which were also confirmed by tumorigenesis experiments in vivo. With overexpression of ARHGAP17 in HCC cells, the p-GSK3β/GSK3β decreased, while the p-β-catenin/β-catenin, Axin1 and APC increased. In conclusion, ARHGAP17 inhibits HCC progression by inactivating the Wnt/β-catenin signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Training Base, General Hospital of Northern Theater Command of Jinzhou Medical University, Shenyang, 110016, Liaoning, China.
- Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China.
- Graduate School, Jinzhou Medical University, Jinzhou, 121000, Liaoning, China.
- Department of Immunology, The College of Basic Medical Sciences, China Medical University, Shenyang, 110122, Liaoning, China.
- Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110016, Liaoning, China. zhang_wei_1980@163.com.
Förderung
- Natural Science Foundation of Liaoning Province
- the Joint Program of Key R&D Programs of Liaoning Province
- the R&D PROGRAMME FOR MAJOR technological innovations of Shenyang City
Zitieren
APA
Fan, S., Zhao, H., Li, C., Chen, X., Sun, M., Chen, F., Long, C., Zhou, Y., Nan, B., Zhao, H., & Zhang, W. (2025). ARHGAP17 Inhibits Hepatocellular Carcinoma Progression by Inactivation of Wnt/β-Catenin Signaling Pathway. Biochemical Genetics. https://doi.org/10.1007/s10528-024-10822-5
Vancouver
Fan S, Zhao H, Li C, Chen X, Sun M, Chen F, et al. ARHGAP17 Inhibits Hepatocellular Carcinoma Progression by Inactivation of Wnt/β-Catenin Signaling Pathway. Biochemical Genetics. 2025. doi:10.1007/s10528-024-10822-5
BibTeX
@article{Fan2025,
author = {Fan, Sirui and Zhao, Hongqing and Li, Cheng and Chen, Xing and Sun, Mingjie and Chen, Fengyang and Long, Chao and Zhou, Yinghui and Nan, Boyuan and Zhao, Hao and Zhang, Wei},
title = {ARHGAP17 Inhibits Hepatocellular Carcinoma Progression by Inactivation of Wnt/β-Catenin Signaling Pathway},
journal = {Biochemical Genetics},
year = {2025},
doi = {10.1007/s10528-024-10822-5}
}
EUVIMED